Last updated: February 16, 2026
Product Overview
NDC 00069-1520 is a prescription medication manufactured by Boehringer Ingelheim. It is identified as Spiriva HandiHaler (tiotropium bromide inhalation powder). Approved for the management of chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis, its patent protections extend to primary formulations and delivery devices.
Market Scope and Epidemiology
COPD affects an estimated 16 million Americans and accounts for approximately 150,000 deaths annually in the U.S. (CDC, 2022). The global COPD market was valued at approximately $9 billion in 2022, with inhaled bronchodilators comprising a significant share. Tiotropium's market penetration remains high due to its efficacy and once-daily dosing.
Competitive Landscape
Major competitors include:
- GSK: Advair (fluticasone/salmeterol)
- Novartis: Ultibro (indacaterol/glycopyrronium)
- Teva: RespiClick (umeclidinium/vilanterol)
- Other: Breezhaler (lenacapavir), which may influence volume shifts.
Tiotropium faces competition from both inhaled corticosteroid/long-acting beta-agonist (ICS-LABA) combinations and newer long-acting muscarinic antagonists (LAMA).
Pricing Overview
The listed wholesale acquisition cost (WAC) for NDC 00069-1520 is approximately $300 for a 30-dose inhaler. Actual out-of-pocket costs vary based on insurance and pharmacy benefits, but cash prices often range from $250 to $350 per inhaler.
Historical Price Trends
Since the introduction in 2004, the price has remained relatively stable, with minor fluctuations. The introduction of generic tiotropium inhalers, such as from Teva, in 2020, has pressured the brand's pricing, prompting the manufacturer to maintain premium branding and patents in faster-to-generic markets.
Market Projection and Volume Trends
The COPD drug market is expected to grow at a CAGR of 4% through 2028, driven by aging populations and increased diagnosis rates. Tiotropium's sales are projected to reach $2.5 billion globally by 2028, accounting for approximately 28% of the inhaler market segment.
Annual sales volume for this NDC is approximately 2 million units in the U.S., with steady growth expected due to expanding COPD awareness and treatment adherence initiatives.
Pricing Forecasts (Next 5 Years)
- Stable Pricing for Brand: WAC likely remains within the $280-$330 range, as patent protections and market exclusivity persist until at least 2025.
- Impact of Generics: Expect a decline in average unit prices as generics gain market share, potentially lowering WAC by 15-20%.
- Insurance and Rebates: Net prices will decrease further when factoring rebates, discounts, and formulary placements.
Market Risks and Opportunities
- Patent Expiry and Generics: Generic versions stretching market share post-2025 could reduce per-unit revenue.
- Introduction of Newer Inhalers: Emerging long-acting muscarinic and beta-agonist combos present competitive threats, possibly limiting price growth.
- Expansion into Emerging Markets: Growing COPD prevalence in Asia and Latin America offers expansion opportunities, albeit with price sensitivity considerations.
| Summary of Financial Data |
Aspect |
Details |
| Current WAC (U.S.) |
Approx. $300 per 30-dose inhaler |
| Units Sold (U.S.) |
Approx. 2 million annually |
| Global Sales (2022) |
$1.2 billion (estimated) |
| Forecasted Market (2028) |
$2.5 billion globally |
| Price Trend (Next 5 years) |
Stable with potential decline due to generics |
Key Takeaways
- NDC 00069-1520’s pricing is stable but faces pressure from generic entrants after 2025.
- The drug’s market remains sizable, with consistent sales driven by COPD prevalence.
- Future price increases are unlikely; volume growth and market expansion are primary revenue drivers.
- Competitive inhalers and combination therapies could impact market share and pricing.
- Strategic markets include the U.S., Europe, and emerging economies with rising COPD rates.
FAQs
-
When will generic versions of tiotropium inhalers be available?
Likely post-2025, following patent expirations and FDA approvals.
-
How do rebates influence the net price of this medication?
Rebates and discounts reduce the real transaction price paid by payers, often lowering net revenue than the WAC suggests.
-
What factors could accelerate or delay market share loss?
Patent litigation outcomes, regulatory approvals of competing inhalers, and formulary decisions.
-
Are there any upcoming formulations that could affect pricing or market share?
Yes, new combination inhalers with improved delivery mechanisms may reshape competitive dynamics.
-
What markets outside the U.S. show potential for growth?
Europe, Japan, China, and other emerging markets with increasing COPD prevalence.
Sources
[1] Centers for Disease Control and Prevention (CDC), 2022. COPD Statistics.
[2] IQVIA, 2022. Global COPD Market Data.
[3] FDA, 2023. Approved Drug Product Labels.
[4] Boehringer Ingelheim Annual Reports, 2022.
[5] EvaluatePharma, 2022. Market Forecast Reports.
